{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-136028","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.190557+00:00","generated_at":"2026-06-28T10:26:00.584699+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eloxx reports Q3 net loss of $9.9M; Phase 2 CF data on track for Q4 2021","bullets":["Net loss of $9.9M ($0.11/share) vs $6.6M loss; R&D spending rose to $5.2M.","Cash $52.4M as of Sep 30, 2021; expected to fund operations into Q1 2023.","Entered debt facility with Hercules Capital for up to $30M, initial draw $12.5M.","Appointed Dr. Ali Hariri as Chief Medical Officer.","FDA Fast Track designation for ELX-02; Phase 2 monotherapy data expected Q4 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-136028","json":"https://secwatch.observer/filing/0001104659-21-136028.json","markdown":"https://secwatch.observer/filing/0001104659-21-136028.md","text":"https://secwatch.observer/filing/0001104659-21-136028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921136028/0001104659-21-136028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921136028/tm2132381d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:26:00.584699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}